Bertelli G, Pronzato P, Amoroso D, Cusimano M P, Conte P F, Montagna G, Bertolini S, Rosso R
Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy.
Breast Cancer Res Treat. 1988 Dec;12(3):307-10. doi: 10.1007/BF01811244.
The possible estrogenic effects of tamoxifen on plasma lipids and antithrombin III levels were investigated in 91 breast cancer patients. Mean values of total, HDL and LDL cholesterol, triglycerides, glucose, uric acid, and antithrombin III were evaluated in 55 patients on adjuvant tamoxifen for at least 3 months and compared with those found in 36 patients on no therapy. Total cholesterol, LDL cholesterol, and antithrombin III levels were significantly lower in treated patients (p less than 0.05). Our results support the hypothesis of a partial agonist action of this antiestrogen, although general clinical practice suggests that tamoxifen-related thrombotic events are rare.
在91例乳腺癌患者中研究了他莫昔芬对血脂和抗凝血酶III水平可能的雌激素样作用。对55例接受辅助他莫昔芬治疗至少3个月的患者评估了总胆固醇、高密度脂蛋白胆固醇、低密度脂蛋白胆固醇、甘油三酯、葡萄糖、尿酸和抗凝血酶III的均值，并与36例未接受治疗的患者的相应均值进行比较。治疗患者的总胆固醇、低密度脂蛋白胆固醇和抗凝血酶III水平显著较低（p<0.05）。我们的结果支持这种抗雌激素具有部分激动剂作用的假说，尽管一般临床实践表明与他莫昔芬相关的血栓形成事件很少见。
